Recro Pharma (REPH) Misses Q2 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Reports Second Quarter 2020 Financial Results
August 10, 2020 7:01 AM EDTLaunches Clinical Trial Materials Business and Secures New Customers
Company to Host Conference Call Today at 8:00 a.m. ET
MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Â Recro (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today reported financial results for the three and six months ended June 30, 2020.
As the global COVID-19 situation continues to evolve, we have... More
